Collaborations & Alliances

Voyager Therapeutics, Sanofi Genzyme Restructure Gene Therapy Alliance

Voyager gains worldwide rights to VY-HTT01 Huntington’s disease program and ex-U.S. rights to VY-FXN01 Friedreich’s ataxia program for $10 million upfront

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Voyager Therapeutics, Inc. and Sanofi Genzyme have restructured their gene therapy partnership under which Voyager gains worldwide rights to the VY-HTT01 Huntington’s disease program and ex-U.S. rights to the VY-FXN01 Friedreich’s ataxia program. The ex-U.S. rights to VY-FXN01 are, in turn, transferred from Voyager to Neurocrine Biosciences under the terms of their collaboration from January 2019. Additionally, Sanofi Genzyme obtains exclusive option rights to select novel AAV capsids owned or c...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters